GeoVax Expands Strategic Footprint in Europe, Targeting Vaccine and Cancer Therapy Development

GeoVax Labs, a clinical-stage biotechnology company, is expanding its global presence by establishing a strategic foothold in the United Kingdom, signaling a significant move to enhance its vaccine and immuno-oncology development capabilities.

The company is actively seeking a UK location that aligns with its development strategy, building upon existing connections in the region. Key partnerships include collaboration with Professor Teresa Lambe from the Oxford Vaccine Group, who recently joined GeoVax's Scientific Advisory Board and played a crucial role in developing the Oxford/AstraZeneca COVID-19 vaccine.

GeoVax's European expansion encompasses multiple strategic elements, including manufacturing partnerships with Oxford Biomedica PLC and technology licensing agreements with ProBioGen AG. The company has also retained Dr. Deborah Spencer to coordinate initiatives across the UK and Europe, demonstrating a comprehensive approach to international collaboration.

This expansion is particularly significant for two primary research areas: infectious disease vaccine development and immuno-oncology. The company's lead immuno-oncology candidate, Gedeptin®, is currently in clinical development for advanced head and neck cancers and shows potential for treating various solid tumors when combined with immune checkpoint inhibitors.

President and CEO David Dodd emphasized the importance of this strategic move, highlighting the potential for enhanced research and development capabilities through global collaboration. The expansion represents a critical milestone in GeoVax's mission to develop innovative solutions for challenging medical conditions.

The company's existing portfolio includes a next-generation COVID-19 vaccine, GEO-CM04S1, which is currently undergoing multiple Phase 2 clinical trials targeting various patient populations, including immunocompromised individuals and those with chronic conditions.